Expert perspectives in ulcerative colitis: An interview with Dr Peter Irving Ulcerative colitis (UC) is a debilitating inflammatory bowel disease (IBD) affecting approximately 1 in 250 people in the UK.1 Galapagos UK Medical Advisor, Claire Hamilton spoke with Dr Peter Irving on the main issues affecting patients with UC in the UK today. What should we expect to see when patients present with UC? UC causes a variety of symptoms, but mainly rectal bleeding, diarrhoea and urgency. I think...
We are Galapagos UK: The unknown is our comfort zone. Who we are We are Galapagos, a pioneering biotechnology company, founded in Belgium in 1999 by our CEO Onno van de Stolpe, focused on discovering and developing innovative medicines to improve peoples’ lives. We have over 1000 employees in 10 international locations including the UK, Belgium, Netherlands, France, Germany, Italy and Spain. The UK operation of Galapagos was set up in 2020, aiming to offer patients in the UK new and improved...
Looking to the future in inflammatory bowel disease (IBD) care: Perspectives from Professor Charlie Lees Professor Charlie Lees is a Consultant Gastroenterologist in the Edinburgh IBD Unit, and Professor of Gastroenterology at the University of Edinburgh. He will be presenting the talk “IBD 2025” at the Galapagos UK symposium, “The evolution of IBD care: recent advances and future perspectives” at 16:05–16:45, 25th January 2021 during the British Society of Gastroenterology (BSG) Campus. Dr...
Switching from intravenous to subcutaneous infliximab biosimilar (Remsima®) in adult patients with inflammatory bowel disease: experience at an NHS trust Dr. Ajay Verma, consultant gastroenterologist and physician, and Anusha Patel, regional homecare lead pharmacist and high cost medicines pharmacist, at Kettering General Hospital NHS Trust, share their experience of implementing a switch from intravenous (IV) to subcutaneous (SC) infliximab biosimilar for stable patients with inflammatory...
Tillotts LOGIC Education is an educational programme for gastrointestinal healthcare professionals, organised and funded by Tillotts, as part of our commitment to reinvest in the NHS. We provide award winning educational initiatives, including fully funded modules to support IBD nurse education and an annual event to encourage networking and recognise excellence. During the COVID-19 pandemic, we have expanded Tillotts LOGIC to include online resources featuring the latest topics in IBD....
As we all know COVID-19 has impacted everyone’s lives this year and changed the way in which we all now work and interact with each other; for us this meant that face to face training was no longer possible. With this realisation our Professional Education team knew it was important to rapidly adapt and change our training offering to ensure that we could continue to support the needs of our customers throughout the pandemic. Blended and interactive learning has always been something our...
BSG CAMPUS BEGINS
40+ hours of live and on-demand webinar sessions focusing
on the key areas of gastroenterology
A electronic poster gallery featuring 445+ posters which
will inspire you with new initiatives and research
A unique platform that connects you with your colleagues,
peers, and industry experts